Compare PBH & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBH | HTFL |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2004 | 2025 |
| Metric | PBH | HTFL |
|---|---|---|
| Price | $47.81 | $56.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $67.80 | $47.22 |
| AVG Volume (30 Days) | 496.7K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $975,777,000.00 | $176,034,000.00 |
| Revenue This Year | $17.03 | $41.33 |
| Revenue Next Year | $6.06 | $24.23 |
| P/E Ratio | $81.10 | ★ N/A |
| Revenue Growth | 36.77 | ★ 39.92 |
| 52 Week Low | $42.62 | $20.13 |
| 52 Week High | $71.07 | $57.25 |
| Indicator | PBH | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 66.26 |
| Support Level | $47.61 | $46.46 |
| Resistance Level | $50.00 | N/A |
| Average True Range (ATR) | 1.41 | 3.08 |
| MACD | 0.18 | 0.52 |
| Stochastic Oscillator | 46.39 | 90.44 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.